Your browser doesn't support javascript.
loading
Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.
Yeter, Hasan H; Derici, Ulver; Arinsoy, Turgay; Altok, Kadriye; Erten, Yasemin; Guz, Galip.
Afiliação
  • Yeter HH; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Derici U; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Arinsoy T; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Altok K; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Erten Y; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Guz G; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
Rom J Intern Med ; 60(1): 56-65, 2022 Mar 01.
Article em En | MEDLINE | ID: mdl-34449174
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Síndrome Hemolítico-Urêmica Atípica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Síndrome Hemolítico-Urêmica Atípica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article